Ascendis nets $112M for PhIII growth hormone trial

dollar

Ascendis Pharma ($ASND) is aiming to raise at least $112 million (€102 million) to move its long-acting growth hormone through a late-phase trial. The offering is intended to give Ascendis the means to carry out a Phase III growth hormone deficiency study while advancing other candidates that have yet to enter the clinic.

Copenhagen, Denmark-based Ascendis is offloading more than 6 million shares for $19 a pop. That would see Ascendis net $112 million, after costs, although the total could increase if the underwriters take up an option on additional shares. Either way, Ascendis is set to add a considerable sum of money to its cash pile. Ascendis closed out June with €91 million in the bank.

The money will go toward a Phase III trial of TransCon Growth Hormone. Ascendis is set to enroll the first patient in the study by the end of the year. Over the duration of the 52-week trial, Ascendis is looking to show that its once-weekly growth hormone formulation can hold its own against Pfizer’s ($PFE) Genotropin. If its drug triggers comparable improvements in annualized height velocity, Ascendis thinks the compliance benefits of the once-weekly regimen will enable it to take market share.

Featured Webinar

From Concept to Market: Overcoming the Challenges of Manufacturing and Clinical Trials

In this webinar we will reveal the inner workings of the manufacturing and pharmacy department of a CRO/CDMO, so you understand the different regulatory and operational considerations faced by a clinical research pharmacy.

Learn how CRO/CDMOs successfully address operational and regulatory challenges for pharmaceutical and biotechnology clients; and how this can make the difference between study success or failure.

Ascendis is tackling the Phase III without the support of a larger partner. As such, the Danish drug developer will need deep pockets to activate approximately 100 sites, enroll 150 patients, treat them over the course of a year and package the data up for regulators. Study completion is currently penciled in for December 2018. A clearer picture of how the trial is progressing is due to emerge when Ascendis provides an update on enrollment in the first half of next year.

If the trial is a success, it will provide Ascendis with its first commercial product and raise hopes for its pipeline of assets based on the same TransCon technology. The technology takes a drug and renders it inactive. Once administered, the formulation releases the original active molecule over time. In doing so, Ascendis thinks it can create sustained-release formulations of existing drugs. Some of the $100 million will go toward work to apply the technology to parathyroid hormone and c-type natriuretic peptide.

Ascendis also has partnerships with Genentech and Sanofi ($SNY). Genentech turned to Ascendis for help making a formulation of age-related macular edema drug Lucentis that needs administering as rarely as twice a year. And Sanofi is running preclinical tests on long-acting diabetes treatments.

Suggested Articles

Ironwood had once hyped this drug as a $2 billion-a-year asset, but IW-3718 has failed to live up to its high expectations.

The company describes the continuous glucose monitor as the world’s smallest and thinnest diabetes sensor, with a disc about the size of two pennies.

Junshi’s PD-1 blocker is already approved in China for metastatic melanoma, but the Shanghai-based biotech may soon add throat cancer to its label.